CJC-1295 – Research Use Only

For research use only. Not for human consumption. Not for veterinary use. Not a medicinal product.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been investigated in scientific research relating to peptide chemistry, receptor pharmacology and endocrine signalling. The compound was developed as a modified form of human growth hormone-releasing factor and has attracted research interest because of its distinctive molecular structure and extended stability in experimental settings.

Product Overview

CJC-1295 is supplied as a research compound for suitably qualified researchers conducting controlled laboratory investigations. Scientific literature has examined the molecular and pharmacological characteristics of this peptide, including its interaction with GHRH receptors and associated signalling pathways.

Research has investigated the behaviour of CJC-1295 in experimental systems, including studies examining pharmacokinetic characteristics and biological responses. Published work has also examined the relationship between the compound and growth hormone-related signalling under defined research conditions. These findings relate to specific experimental models and should not be interpreted as evidence of suitability, efficacy or safety for human or veterinary use.

The modified structure of CJC-1295 has been studied in relation to its stability and interaction with circulating proteins. Research has examined how these structural characteristics distinguish the compound from shorter-acting GHRH sequences, providing a defined subject for peptide and receptor research.

This product is supplied solely as a research material. It is not supplied as a food, food supplement, cosmetic, medicine, veterinary medicine or therapeutic product. No claims are made that CJC-1295 can diagnose, treat, cure, prevent or alleviate any disease, illness or medical condition.

Research Applications

For suitably qualified researchers, CJC-1295 may be of interest in areas including peptide chemistry, analytical chemistry, receptor pharmacology, molecular biology and endocrine research. Potential laboratory investigations may include peptide identification, analytical characterisation, stability assessment, receptor-binding studies and controlled investigations of GHRH-associated signalling pathways.

Researchers should independently determine whether the material is appropriate for their intended experimental application. Appropriate laboratory procedures, validated analytical methods, suitable protective equipment and relevant safety controls should be used when handling research compounds.

No instructions for administration, dosage, injection, reconstitution or personal use are provided with this product. It is intended exclusively for legitimate laboratory research conducted by appropriately qualified personnel and within suitable controlled laboratory environments.

Product Characteristics

Product: CJC-1295
Classification: Synthetic GHRH analogue
Research area: Peptide and receptor signalling research
Product type: Research material
Quantity: 10mg

CJC-1295 should be distinguished from any authorised pharmaceutical preparation or medicinal product. The existence of clinical research involving a compound does not mean that a research-grade material supplied through a website is itself an authorised medicinal product.

Researchers should consider the specific characteristics of their experimental model when evaluating published information. Research observations may differ according to analytical methodology, peptide preparation, receptor system, biological model and experimental conditions.

Quality & Laboratory Research

Research compounds should be handled by suitably qualified personnel using appropriate laboratory procedures and relevant safety practices. Researchers are responsible for confirming the identity, suitability and analytical characteristics of materials required for their particular experimental work.

Researchers should review applicable product specifications and analytical documentation before commencing laboratory investigations where such information is available. Storage, handling and disposal should follow appropriate laboratory procedures, institutional requirements and relevant safety practices.

The material should only be used within suitable research environments and by personnel familiar with the handling of synthetic peptide materials. Users are responsible for ensuring that their intended research activities comply with applicable legislation and institutional requirements.

UK Regulatory Notice

The regulatory status of products in the United Kingdom can depend on factors including composition, intended purpose, pharmacological properties, wording and presentation. The MHRA considers explicit and implicit claims together with how products are presented through websites, packaging, advertising and promotional material when determining whether a product may fall within the definition of a medicinal product.

Accordingly, this listing is deliberately limited to factual research information. CJC-1295 is presented solely as a laboratory research compound and is not marketed as a treatment, medicine, supplement or consumer health product.

For research use only. Not for human consumption. Not for veterinary use. Not a medicinal product. Not intended to diagnose, treat, cure or prevent any disease or medical condition.